by Eric Christianson | Aug 18, 2021 | Cardiovascular Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
As one of the few significant new treatment options approved for reducing the risk of cardiovascular events since statins were approved about 30 years ago, when should icosapent ethyl (Vascepa) actually be used? Icosapent ethyl, sold as Vascepa by Amarin, is a...
by Eric Christianson | Jun 27, 2021 | Cardiovascular Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
In this article, we take a look at the Alpha-2 Adrenergic Agonists. In comparing Alpha-2 Adrenergic Agonists, we will primarily look at dosing, adverse effects, and notable indications. Clonidine is FDA-approved for attention deficit hyperactivity disorder (ADHD),...
by Eric Christianson | May 30, 2021 | Cardiovascular Medication and Disease State Clinical Pearls, Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
I was asked about the clinical of thiazides and hyperglycemia. To be honest, studies aren’t that great surrounding this question, and the main ones I’m aware of and could find were very old. Here’s a quick breakdown of a couple of studies on the risk...
by Eric Christianson | May 26, 2021 | Cardiovascular Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
I got asked a question the other day about spironolactone. Specifically, how common is gynecomastia with spironolactone? Before I answer that question, let’s take a look at some of the common clinical pearls with spironolactone. Spironolactone classified as a...
by Eric Christianson | May 16, 2021 | Cardiovascular Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
You will see antiarrhythmics used in clinical practice. They are typically prescribed by cardiovascular specialists, but we wanted to provide an antiarrhythmic comparison chart because as a healthcare professional, you still need to monitor for risks and drug...
by Eric Christianson | Mar 28, 2021 | Cardiovascular Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
Sacubitril/valsartan (ARNI) is getting more attention in the guidelines with regards to its use in heart failure (specifically HFrEF). Many patients are already on an ACE and making the transition from an ACE inhibitor to an ARNI is likely something you will come...
